IBB vs. CANC
Compare and contrast key facts about iShares Nasdaq Biotechnology ETF (IBB) and Tema Oncology ETF (CANC).
IBB and CANC are both exchange-traded funds (ETFs), meaning they are traded on stock exchanges and can be bought and sold throughout the day. IBB is a passively managed fund by iShares that tracks the performance of the NASDAQ Biotechnology Index. It was launched on Feb 5, 2001. CANC is an actively managed fund by Tema. It was launched on Aug 14, 2023.
Performance
IBB vs. CANC - Performance Comparison
Loading graphics...
IBB vs. CANC - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
IBB iShares Nasdaq Biotechnology ETF | 0.12% | 27.98% | -2.41% | 3.76% | -13.69% | -5.58% |
CANC Tema Oncology ETF | 5.69% | 42.92% | -5.37% | 510.51% | -85.34% | -51.82% |
Returns By Period
In the year-to-date period, IBB achieves a 0.12% return, which is significantly lower than CANC's 5.69% return.
IBB
- 1D
- 4.32%
- 1M
- -3.65%
- YTD
- 0.12%
- 6M
- 17.17%
- 1Y
- 32.33%
- 3Y*
- 9.65%
- 5Y*
- 2.46%
- 10Y*
- 6.84%
CANC
- 1D
- 4.66%
- 1M
- -2.88%
- YTD
- 5.69%
- 6M
- 27.93%
- 1Y
- 52.46%
- 3Y*
- 140.00%
- 5Y*
- —
- 10Y*
- —
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
IBB vs. CANC - Expense Ratio Comparison
IBB has a 0.47% expense ratio, which is lower than CANC's 0.75% expense ratio.
Return for Risk
IBB vs. CANC — Risk / Return Rank
IBB
CANC
IBB vs. CANC - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for iShares Nasdaq Biotechnology ETF (IBB) and Tema Oncology ETF (CANC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| IBB | CANC | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 1.35 | 1.94 | -0.59 |
Sortino ratioReturn per unit of downside risk | 1.91 | 2.59 | -0.68 |
Omega ratioGain probability vs. loss probability | 1.25 | 1.32 | -0.08 |
Calmar ratioReturn relative to maximum drawdown | 2.41 | 3.86 | -1.45 |
Martin ratioReturn relative to average drawdown | 8.61 | 13.76 | -5.15 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading graphics...
Sharpe Ratios by Period
| IBB | CANC | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 1.35 | 1.94 | -0.59 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.11 | — | — |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.29 | — | — |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.26 | -0.04 | +0.29 |
Correlation
The correlation between IBB and CANC is 0.53, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.
Dividends
IBB vs. CANC - Dividend Comparison
IBB's dividend yield for the trailing twelve months is around 0.23%, more than CANC's 0.05% yield.
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
IBB iShares Nasdaq Biotechnology ETF | 0.23% | 0.23% | 0.29% | 0.26% | 0.31% | 0.21% | 0.21% | 0.33% | 0.20% | 0.30% | 0.19% | 0.03% |
CANC Tema Oncology ETF | 0.05% | 0.06% | 3.00% | 0.56% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Drawdowns
IBB vs. CANC - Drawdown Comparison
The maximum IBB drawdown since its inception was -62.85%, smaller than the maximum CANC drawdown of -97.53%. Use the drawdown chart below to compare losses from any high point for IBB and CANC.
Loading graphics...
Drawdown Indicators
| IBB | CANC | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -62.85% | -97.53% | +34.68% |
Max Drawdown (1Y)Largest decline over 1 year | -11.65% | -12.40% | +0.75% |
Max Drawdown (5Y)Largest decline over 5 years | -39.82% | — | — |
Max Drawdown (10Y)Largest decline over 10 years | -39.82% | — | — |
Current DrawdownCurrent decline from peak | -4.88% | -56.19% | +51.31% |
Average DrawdownAverage peak-to-trough decline | -21.30% | -73.91% | +52.61% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 3.47% | 3.61% | -0.14% |
Volatility
IBB vs. CANC - Volatility Comparison
iShares Nasdaq Biotechnology ETF (IBB) and Tema Oncology ETF (CANC) have volatilities of 8.62% and 8.36%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.
Loading graphics...
Volatility by Period
| IBB | CANC | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 8.62% | 8.36% | +0.26% |
Volatility (6M)Calculated over the trailing 6-month period | 14.53% | 16.34% | -1.81% |
Volatility (1Y)Calculated over the trailing 1-year period | 24.08% | 27.24% | -3.16% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 21.87% | 285.66% | -263.79% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 23.37% | 285.66% | -262.29% |